¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, Ä¡·á À¯Çüº°, À¯Åë ä³Îº°, Áö¿ªº°
Biosimilars Market, By Drug Class, By Therapy Type, By Distribution Channel, By Geography
»óǰÄÚµå : 1672730
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,511,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 10,128,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,469,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀº 2025³â¿¡´Â 425¾ï 3,000¸¸ ´Þ·¯¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. 2032³â¿¡´Â 1,363¾ï 7,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ°í, 2025-2032³âÀÇ CAGRÀº 18.1%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 425¾ï 3,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£(2025-2032³â) CAGR 18.10% 2032³â ±Ý¾× ¿¹Ãø 1,363¾ï 7,000¸¸ ´Þ·¯
±×¸². ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀåÀÇ Áö¿ªº° Á¡À¯À²(%)(2025³â)
Biosimilars Market-IMG1

¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå ¼ºÀå ¿øµ¿·ÂÀº ¼¼°è ÀÇ·á ºñ¿ë »ó½Â°ú ºí·Ï¹ö½ºÅÍ »ý¹° Á¦Á¦ÀÇ Æ¯Çã ¸¸·áÀÔ´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰÀº ¾Ï, ´ç´¢º´, ÀÚ°¡¸é¿ª Áúȯ µîÀÇ ¸¸¼º Áúȯ¿¡ ´ëÇÑ Àú·ÅÇÑ Ä¡·á ¿É¼ÇÀ» ±âÀçÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰÀº ±âÁØ »ý¹° Á¦Á¦¿¡ ºñÇØ »ó´çÇÑ ºñ¿ë Àý°¨ÀÌ °¡´ÉÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, ÇÊ±×¶ó½ºÆÀÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÎ ÀÚÁö¿À´Â ¿ø·¡ÀÇ »ý¹°Á¦Á¦ÀÎ ³ëÀÌÆ÷°Õ¿¡ ºñÇØ 15% ³·Àº °¡°ÝÀ¸·Î Ãâ½ÃµÇ¾ú½À´Ï´Ù. ¹Ì±¹, EU, ÀϺ» µî ÁÖ¿ä ½ÃÀå¿¡¼­´Â ¸íÈ®ÇÑ Áöħ¿¡ µû¶ó ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ ±ÔÁ¦ ´ç±¹¿¡ ÀÇÇÑ ½ÂÀεµ Áõ°¡ÇÏ°í ½ÃÀå ÁøÀÔÀÌ ¿ëÀÌÇØÁö°í ÀÖ½À´Ï´Ù. ÀÌ ¶§¹®¿¡ ¸¹Àº ½ÅÈï ±â¾÷µéÀÌ °Å´ëÇϰí À¯¸®ÇÑ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå¿¡ ÁøÃâÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå ¼ºÀå ¿øµ¿·ÂÀº ¼¼°èÀÇ ¸¸¼º Áúȯ ÀÌȯÀ² Áõ°¡¿Í Á¦ÇÑµÈ ÀÇ·á ¿¹»êÀÔ´Ï´Ù. ÀÌ ¶§¹®¿¡ »ý¹°Á¦Á¦¸¦ ´ëüÇÏ´Â Àúºñ¿ë ¹ÙÀÌ¿À½Ã¹Ð·¯ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¸¹Àº ´ëÈ÷Æ® »ý¹° Á¦Á¦´Â 2018-2026³âÀÇ ¿¹Ãø ±â°£ µ¿¾È ƯÇã º¸È£¸¦ ÀÒÀ» °ÍÀ¸·Î ¿¹»óµÇ¹Ç·Î ¹ÙÀÌ¿À½Ã¹Ð·¯ ÁøÀÔ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ÀÎÇø¯½Ã¸¿°ú ¾Æ´Þ¸®¹«¸¿Àº 2024³â±îÁö ¹ÙÀÌ¿À½Ã¹Ð·¯ °æÀï¿¡ Á÷¸éÇØ °¡Àå ³ôÀº ¼öÀÍÀ» ¾òÀº »ý¹°ÇÐÀû Á¦Á¦ Áß ÇϳªÀÔ´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú Á¦Ç°ÀÇ Ãâ½Ã, ´ë±â¾÷ÀÇ ¸¶ÄÉÆÃ È®´ë Ȱµ¿ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå - Äڷγª ¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå, ¾àÁ¦ Ŭ·¡½ºº°(2020-2032³â), 10¾ï ´Þ·¯

Á¦6Àå ¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå, Ä¡·á À¯Çüº°(2020-2032³â), 10¾ï ´Þ·¯

Á¦7Àå ¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå, À¯Åë ä³Îº°(2020-2032³â), 10¾ï ´Þ·¯

Á¦8Àå ¼¼°èÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ½ÃÀå, Áö¿ªº°(2020-2032³â), 10¾ï ´Þ·¯

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ¾Ö³Î¸®½ºÆ® Ãßõ

Á¦11Àå Âü°í¹®Çå°ú Á¶»ç¹æ¹ý

KTH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Biosimilars Market is estimated to be valued at USD 42.53 Bn in 2025 and is expected to reach USD 136.37 Bn by 2032, growing at a compound annual growth rate (CAGR) of 18.1% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 42.53 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 18.10% 2032 Value Projection: USD 136.37 Bn
Figure. Biosimilars Market Share (%), By Region 2025
Biosimilars Market - IMG1

Global biosimilars market growth is driven by rising healthcare costs worldwide and the expiration of blockbuster biologics patents. Biosimilars provide affordable treatment options for chronic diseases such as cancer, diabetes, and autoimmune disorders. These offer significant cost savings as compared to reference biologics. For example, Filgrastim's biosimilar Zarzio was launched at a 15% lower price compared to original biologic Neupogen. Regulatory approvals for biosimilars have also increased in major markets like the U.S, EU, and Japan following clear guidelines, thus, easing market entry. This has attracted many emerging players to the large and lucrative biosimilars market.

Market Dynamics:

Global biosimilars market growth is driven by factors like rising chronic disease prevalence rates worldwide coupled with limited healthcare budgets. This has boosted demand for lower-cost biosimilar alternatives to biologics. Many blockbusters biologic drugs are expected to lose patent protection over the forecast period 2018-2026, thus, offering potential for biosimilar entrants. For instance, infliximab and adalimumab are among the highest revenue earning biologics that faced biosimilar competition by 2024. Regulatory approvals and product launches, along with marketing expansion activities by major players can drive the market growth.

Key Features of the Study:

Detailed Segmentation-

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Biosimilars Market - Impact of Coronavirus (COVID-19) Pandemic

5. Global Biosimilars Market, By Drug Class, 2020 - 2032, (USD Bn)

6. Global Biosimilars Market, By Therapy Type, 2020 - 2032, (USD Bn)

7. Global Biosimilars Market, By Distribution Channel, 2020 - 2032, (USD Bn)

8. Global Biosimilars Market, By Region, 2020 - 2032, (USD Bn)

9. Competitive Landscape

10. Analyst Recommendations

11. References and Research Methodology

"

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â